During the past decade, Trial Information Support Line conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Trial Information Support Line" are "Allergy" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "Trial Information Support Line" in a lesser frequency.

Most popular intervention types in "Trial Information Support Line" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Xolair (omalizumab)" (1 trials) and "rhuFab V2 (ranibizumab)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Trial Information Support Line" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Trial Information Support Line". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Trial Information Support Line, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Trial Information Support Line, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".